Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Eric Freeman who wrote (7530)	6/30/1999 9:33:00 PM
From: BlueCrab	Respond to of 8116

Eric, I couldn't have stated the case better. Those interested, get in now - you're only down a buck...

To: Eric Freeman who wrote (7530)	7/6/1999 1:05:00 PM
From: Jim Oravetz	Read Replies (2) \| Respond to of 8116

Cytogen Cancer Treatment Effective In Study July 6, 1999 Dow Jones Newswires PRINCETON, N.J. -- Cytogen Corp. (CYTO) said a study published in Cancer Research supports its prostate specific membrane antigen, or PSMA, as a diagnostic and therapeutic agent for a wide variety of cancers. In a press release Monday, Cytogen said PSMA had enzymatic activity and may regulate one or more metabolic pathways. PSMA is a protein abundantly expressed on the surface of cancer cells. Cytogen holds exclusive worldwide rights to PSMA under a license from Memorial Sloan-Kettering Cancer Center. As reported June 16, Cytogen and Progenics Pharmaceuticals Inc. (PGNX) formed a venture to develop vaccine and antibody-based therapeutic products. Cytogen said the products will use its PSMA technology. Under the terms of the venture agreement, Progenics will conduct preclinical and clinical development of therapeutic antibodies and vaccines that treat prostate and potentially other cancer types. Cytogen will assume exclusive North American marketing rights for products resulting from the venture and have an option to market outside the U.S. Cytogen develops treatments for cancer and urological diseases. Progenics , Tarrytown, N.Y., develops and markets products to treat cancer and viral diseases. Jim